STO · EGTX.ST
Egetis Therapeutics AB (publ)
SEK 10.34SEK 0.00 (0.0%)
Egetis Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 4.44% below the high.
Loading market information…
STO · DVYSR.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Devyser Diagnostics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 56.91% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Devyser Diagnostics AB (publ)’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of SEK 0.06. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Devyser Diagnostics AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Headquartered in Hägersten, Sweden, and established in 2004, Devyser Diagnostics AB (publ) specializes in the development, manufacturing, and global sale of advanced diagnostic kits and solutions for DNA testing. The company's innovative products are crucial for genetic analysis in key medical areas, including hereditary diseases, oncology, and post-transplantation monitoring. Devyser offers a broad array of diagnostic tools, covering applications such as post-transplant management, thalassemia screening, and the detection of various cancers like breast, colorectal, and ovarian. Their portfolio also extends to non-invasive fetal RHD screening, diagnostics for inherited conditions, cystic fibrosis, cardiovascular issues, male infertility, and rapid aneuploidy analysis, complemented by essential accessories. These solutions are utilized for diverse purposes, from diagnosing genetic disorders and guiding targeted cancer treatments to ensuring thorough follow-up care for transplant patients. Furthermore, Devyser provides specialized software programs, including Amplicon Suite and Advyser, which facilitate the processing, analysis, and interpretation of test results, enabling efficient marker screening and patient sample tracking. The company's operations span Sweden, the broader European market, the Middle East, Africa, North and South America, and Asia.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| SEK 67.40M+8.84% vs estimate |
| Q1 2025 | Apr 29, 2025 | -SEK 1.24-129.63% vs estimate | SEK 54.80M-17.42% vs estimate |
|---|
| Q4 2024 | Feb 13, 2025 | -SEK 0.19+66.67% vs estimate | SEK 64.20M-3.02% vs estimate |
|---|
| Q3 2024 | Oct 30, 2024 | -SEK 1.41-31.78% vs estimate | SEK 48.70M-23.93% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 10.34SEK 0.00 (0.0%)
Egetis Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 4.44% below the high.
SEK 70.90+SEK 0.30 (+0.42%)
Humana AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 8.87% below the high.
SEK 9.90+SEK 0.40 (+4.21%)
Vicore Pharma Holding AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 45.72% below the high.
SEK 250.00SEK 0.00 (0.0%)
Stille AB’s quoted price sits in the upper half of its reported 52-week range, 11.66% below the high.
SEK 26.45-SEK 0.50 (-1.86%)
Carasent AB’s quoted price sits in the upper half of its reported 52-week range, 10.19% below the high.
SEK 24.15-SEK 0.10 (-0.41%)
BICO Group AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 5.0% below the high.
SEK 68.40+SEK 1.20 (+1.79%)
Paxman AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.58% below the high.
SEK 11.45-SEK 0.05 (-0.43%)
Saniona AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 59.54% below the high.
